CYP19A1 and breast cancer: Targeting ER function with endocrine therapy is the most common and effective treatment for this subset of breast cancers, but recent data have shown that RET signalling, driven by its ligand GDNF, has a negative impact on the response of ER-positive breast cancer cells to aromatase inhibitors [4] and tamoxifen [5,6].